Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,773 across all filing types
Latest filing 2022-03-01 Remuneration Information
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Remuneration Report 2021 of Evotec SE
Remuneration Information Classification · 1% confidence The document is explicitly titled "Remuneration Report 2021 of Evotec SE". It details the remuneration awarded and owed to the Management Board and Supervisory Board members, discusses fixed and variable compensation components, and references compliance with German corporate law (AktG) and the German Corporate Governance Code (GCGC). This content directly aligns with the definition of a Remuneration Information document, which corresponds to the filing code DEF 14A (Proxy Solicitation & Information Statement often includes this, but the specific definition provided maps directly to compensation details). Reviewing the provided definitions: - 10-K: This is not the full annual report. - AR: This is not a standalone audit report. - DEF 14A: The definition provided is "Report detailing compensation for top executives and directors." This is the most precise match for a 'Remuneration Report'. Although the document mentions it will be presented for approval at the AGM, the document itself is the detailed report on compensation, not the announcement of the vote results (DVA) or the AGM materials (AGM-R). Therefore, DEF 14A is the correct classification.
2022-03-01 English
Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets
Regulatory Filings Classification · 1% confidence The document is labeled as 'Ad-hoc' and contains an 'Inside information acc. to Article 17 MAR' disclosure. It announces a specific corporate event: Bayer discontinuing a clinical development candidate and Evotec regaining rights. This type of material, which is a significant, non-scheduled corporate update required under EU market abuse regulation (MAR), does not fit neatly into standard periodic reports (10-K, IR) or specific financial events (ER, DIV). It is a general regulatory announcement concerning a material business development. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback category for miscellaneous, mandatory regulatory disclosures that are not covered by more specific codes like DIRS, MANG, or TAR.
2022-02-04 English
Report Publication Announcement 2022
Report Publication Announcement Classification · 1% confidence The document is titled "Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements." It explicitly states that it is a preliminary announcement regarding the disclosure dates and locations (URLs) for future Quarterly/Interim statements (which would typically be classified as IR or ER/MDA). Since the document itself is not the financial report but rather an announcement about *when* and *where* the reports will be published, it fits the definition of a Report Publication Announcement (RPA). The document length (2117 chars) is short, supporting the 'announcement' classification over the full report classification.
2022-01-31 English
Report Publication Announcement 2022
Report Publication Announcement Classification · 1% confidence The document is titled "Evotec SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG". It explicitly states that it is a preliminary announcement regarding the disclosure dates and locations for future reports, specifically the 'Annual financial report of the group' and the 'Financial report of the group (half-year/Q2)'. Since the document itself is an announcement about when and where other reports will be published, and not the reports themselves, it fits the definition of a Report Publication Announcement (RPA). The document length (2181 chars) is short, supporting the RPA classification over the full report classification (10-K or IR).
2022-01-31 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement titled 'Total Voting Rights Announcement' from Evotec SE, dated 31.01.2022. It explicitly states the 'Publication of total number of voting rights' and details a 'Conditional capital increase'. This type of regulatory disclosure regarding the total number of shares/voting rights, often mandated by securities laws (here referencing WpHG, the German Securities Trading Act), is a specific type of corporate action notification. While it relates to capital structure, it is not a general financing update (CAP) or a share issue/buyback report (SHA/POS). It is a formal regulatory disclosure concerning voting rights, which fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Total Voting Rights Announcement' and it is not a comprehensive report like 10-K or IR. Given its nature as a mandatory regulatory disclosure via DGAP, RNS is the most appropriate fallback.
2022-01-31 English
DGAP-DD: Evotec SE english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section labeled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of an executive (Dr. Mario Polywka), their position, the nature of the transaction (Purchase of shares by exercising stock options), and the price/volume. This content directly matches the definition for Director's Dealing.
2022-01-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.